Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng
Clin Mol Hepatol. 2022;28(4):725-738.   Published online 2022 Mar 14     DOI: https://doi.org/10.3350/cmh.2022.0015
Citations to this article as recorded by Crossref logo
Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng
Alimentary Pharmacology & Therapeutics.2024;[Epub]     CrossRef
Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection
Tzu-I Chen, Fu-Jen Lee, Wan-Lun Hsu, Yong-Chen Chen, Mingchih Chen
Cancers.2023; 15(4): 1148.     CrossRef
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2023; 29(2): 377.     CrossRef
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome
David S. H. Bell, Terri Jerkins
Diabetes, Obesity and Metabolism.2023; 25(11): 3093.     CrossRef
Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease
Iqra J Mazhar, Mohamed Yasir, Saba Sarfraz, Gandhala Shlaghya, Sri Harsha Narayana, Ujala Mushtaq, Basim Shaman Ameen, Chuhao Nie, Daniel Nechi, Sai Sri Penumetcha
Cureus.2023;[Epub]     CrossRef
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome.2023; (5): 8.     CrossRef
Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives
Lei Miao, Giovanni Targher, Christopher D. Byrne, Luca Valenti, Xiaolong Qi, Ming‐Hua Zheng
Portal Hypertension & Cirrhosis.2022; 1(1): 57.     CrossRef
The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy
Bo Yuan, Jichun Ma, Jing Wang, Jinyong Hao
Frontiers in Endocrinology.2022;[Epub]     CrossRef